



**HAL**  
open science

## Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

C. Buske, M. Dreyling, A. Alvarez-Larrán, J. Apperley, L. Arcaini, C. Besson, L. Bullinger, P. Corradini, M. Giovanni Della Porta, M. Dimopoulos, et al.

### ► To cite this version:

C. Buske, M. Dreyling, A. Alvarez-Larrán, J. Apperley, L. Arcaini, et al.. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 2022, 7 (2), pp.100403. 10.1016/j.esmoop.2022.100403 . hal-03642597

HAL Id: hal-03642597

<https://hal.science/hal-03642597v1>

Submitted on 3 May 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

ORIGINAL RESEARCH

## Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus

C. Buske<sup>1\*</sup>, M. Dreyling<sup>2</sup>, A. Alvarez-Larrán<sup>3</sup>, J. Apperley<sup>4</sup>, L. Arcaini<sup>5,6</sup>, C. Besson<sup>7,8</sup>, L. Bullinger<sup>9,10</sup>, P. Corradini<sup>11</sup>, M. Giovanni Della Porta<sup>12,13</sup>, M. Dimopoulos<sup>14</sup>, S. D'Sa<sup>15</sup>, H. T. Eich<sup>16</sup>, R. Foà<sup>17</sup>, P. Ghia<sup>18</sup>, M. G. da Silva<sup>19</sup>, J. Gribben<sup>20</sup>, R. Hajek<sup>21</sup>, C. Harrison<sup>22</sup>, M. Heuser<sup>23</sup>, B. Kieseewetter<sup>24</sup>, J. J. Kiladjian<sup>25</sup>, N. Kröger<sup>26</sup>, P. Moreau<sup>27</sup>, J. R. Passweg<sup>28</sup>, F. Peyvandi<sup>29,30</sup>, D. Rea<sup>31</sup>, J.-M. Ribera<sup>32</sup>, T. Robak<sup>33</sup>, J. F. San-Miguel<sup>34</sup>, V. Santini<sup>35</sup>, G. Sanz<sup>36,37</sup>, P. Sonneveld<sup>38</sup>, M. von Lilienfeld-Toal<sup>39,40</sup>, C. Wendtner<sup>41</sup>, G. Pentheroudakis<sup>42</sup> & F. Passamonti<sup>43\*</sup>

<sup>1</sup>Institute of Experimental Cancer Research, Department of Internal Medicine III, University Hospital Ulm, Ulm; <sup>2</sup>Department of Medicine III at LMU Hospital, Munich, Germany; <sup>3</sup>Hematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain; <sup>4</sup>Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK; <sup>5</sup>Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia; <sup>6</sup>Department of Molecular Medicine, University of Pavia, Pavia, Italy; <sup>7</sup>Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay; <sup>8</sup>UVSQ, Inserm, CESP, Villejuif, France; <sup>9</sup>Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin; <sup>10</sup>Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; <sup>11</sup>Hematology Division, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan; <sup>12</sup>Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan; <sup>13</sup>Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; <sup>14</sup>Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; <sup>15</sup>UCLH Centre for Waldenström and Neurohaematology, University College London Hospitals NHS Foundation Trust, London, UK; <sup>16</sup>Department of Radiation Oncology, University of Muenster, Münster, Germany; <sup>17</sup>Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome; <sup>18</sup>Strategic Research Program on Chronic Lymphocytic Leukemia and Laboratory of B Cell Neoplasia, Division of Molecular Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; <sup>19</sup>Department Of Hematology, Portuguese Institute of Oncology, Lisbon, Portugal; <sup>20</sup>Barts Cancer Institute, Queen Mary University of London, London, UK; <sup>21</sup>Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; <sup>22</sup>Clinical Director - Haematology, Haemostasis, Palliative Care, Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK; <sup>23</sup>Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany; <sup>24</sup>Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria; <sup>25</sup>Université de Paris, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris, France; <sup>26</sup>Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany; <sup>27</sup>Hematology Department, University Hospital Hotel-Dieu, Nantes, France; <sup>28</sup>Hematology Division, Basel University Hospital, Basel, Switzerland; <sup>29</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan; <sup>30</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; <sup>31</sup>University Medical Department of Hematology and Immunology, France Intergrroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Hôpital Saint-Louis, Paris, France; <sup>32</sup>Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain; <sup>33</sup>Department of Hematology, Medical University of Lodz, Lodz, Poland; <sup>34</sup>Clínica Universidad de Navarra (CUN), Centro de Investigación Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC, Pamplona, Spain; <sup>35</sup>MDS Unit, Hematology, DMSC, AOUC, University of Florence, Florence, Italy; <sup>36</sup>Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia; <sup>37</sup>CIBERONC, IS Carlos III, Madrid, Spain; <sup>38</sup>Erasmus MC Cancer Institute, Department of Haematology, Rotterdam, The Netherlands; <sup>39</sup>Department of Hematology and Medical Oncology, University Hospital Jena, Jena; <sup>40</sup>Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena; <sup>41</sup>Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany; <sup>42</sup>Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland; <sup>43</sup>Department of Medicine and Surgery, University of Insubria, Varese, Italy



Available online 28 January 2022

**Background:** The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group.

**Methods:** This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance.

\*Correspondence to: Prof. Christian Buske, Institute of Experimental Cancer Research, University Hospital Ulm, Germany, Albert-Einstein-Allee 23, 89081 Ulm, Germany. Tel: +49-73150065801/888

E-mail: [christian.buske@uni-ulm.de](mailto:christian.buske@uni-ulm.de) (C. Buske).

\*Prof. Francesco Passamonti, Department of Medicine and Surgery, University of Insubria, Varese, Ospedale di Circolo, Varese, Viale Borri, 57, Varese, Italy. Tel: +39-332-393-648

E-mail: [Francesco.Passamonti@asst-settelaghi.it](mailto:Francesco.Passamonti@asst-settelaghi.it) (F. Passamonti).

2059-7029/© 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Results and conclusion:** The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.

**Key words:** COVID-19, hematological malignancies, consensus manuscript

## INTRODUCTION

The novel SARS-CoV-2 led to a worldwide pandemic in 2020 and has become a major global health concern affecting >220 million people and causing >4.5 million deaths worldwide until September 2021 (<https://coronavirus.jhu.edu/map.html>). COVID-19 is a systemic disease with most of the patients presenting with mild or moderate symptoms. Up to 5%-10%, however, will present severe or life-threatening disease course and dysfunctions, and complications can persist for at least 6 months after diagnosis.<sup>1,2</sup>

Because of immunosuppression, the potential threat of COVID-19 to cancer patients is significant and a higher mortality rate has been documented for multiple cancers worldwide.<sup>3</sup> Immunosuppression is particularly evident in hematological malignancies (HMs) such as leukemias, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), lymphomas, and multiple myeloma (MM). This is based on the fact that malignant transformation in HM affects immunocompetent cells themselves and/or that anticancer treatments targeting the transformed immune cells regularly compromise their normal healthy counterparts. Based on large cohorts,<sup>4,5</sup> international registries,<sup>6</sup> and meta-analysis,<sup>7</sup> the mortality of COVID-19 in HM is high with ~35% of patients dying with documented SARS-CoV-2 infection. Mortality was also assessed in distinct HM as MM,<sup>8</sup> chronic lymphocytic leukemia (CLL),<sup>9</sup> non-Hodgkin's lymphoma (NHL),<sup>10</sup> and in patients who received hematopoietic stem cell transplantation (HSCT),<sup>11</sup> disclosing a fatality rate of 33%, 33%, 34%, and 33%, respectively. In most of these studies, risk factors for worse outcome comprised advanced age, more severe HM type, progressive disease status, and COVID-19 severity. Of note, treatment-mediated immune dysfunction, caused by e.g. chemoimmunotherapy or Bruton's tyrosine kinase (BTK) inhibition is the main driver of the low rate of seroconversion post COVID-19, estimated at 69% in the whole HM population.<sup>12</sup>

The dismal outcome of COVID-19 in HM and the emergence of new virus variants with higher infectivity rate<sup>13</sup> emphasize the need for early introduction of a vaccination program in these patients. It has been convincingly shown, however, that anti-COVID-19 vaccines elicit an impaired antibody response in patients with HM.<sup>14-17</sup> A lower rate of seroconversion (40%-89%) has been reported in lymphoproliferative disorders due to disease and/or drug-induced B-cell or plasma cell depletion and/or disruption of the B-cell receptor signaling pathway.<sup>18-23</sup> A longer time from their exposure can favor immune response in these conditions.<sup>21,23-28</sup> Myeloid neoplasms have been studied less: the rate of post vaccine seroconversion seems higher (85%-90%) in MPNs and chronic myeloid leukemia (CML),<sup>26,29-32</sup>

except in patients receiving Janus kinase (JAK) inhibitors (near 60%).<sup>30</sup>

Based on the known frailty of HMs, the rapidly changing situation during the pandemic with its multiple infectious waves and the spread of distinct virus variants worldwide, and the highly divergent situation of the health system in different countries, management of HM patients has focused on avoiding hospital stays and reducing immunocompromising treatments, up to delaying initiation of anticancer treatment if thought feasible. Most of this decision making was based on little evidence, raising many open questions with regard to the optimal care for HM during the pandemic. Thus, there is an urgent need for consensus statements on how to clinically manage HM patients in this unprecedented situation of the COVID-19 pandemic. To provide guidance for the clinical care in HM, a large interdisciplinary and international committee on behalf of the European Society for Medical Oncology (ESMO) and European Hematology Association (EHA) established an international and multidisciplinary group of experts to discuss clinical evidence (consensus) and to provide expert advice on areas of controversy in the management of HM patients in the pandemic. By this, a consensus was developed offering a comprehensive set of recommendations including a consensus on COVID-19 diagnosis, treatment, and mitigation strategies for the heterogeneous group of HMs. This concise consensus statement will help to optimize clinical management in HMs and support multidisciplinary teams caring for HM patients in clinical decision making.

## METHODS

A steering committee (SC) appointed by the ESMO and EHA boards prepared a series of questions to be voted upon at the consensus meeting. The multidisciplinary expert panel was compiled based on nominations from ESMO and EHA. The SC consisted of 35 members with expertise across HMs, coordinated by two members, Christian Buske and Francesco Passamonti, each representing the ESMO and EHA, respectively. In order to develop the clinical questions to be addressed at the consensus meeting, the SC reviewed relevant clinical evidence and basic research in HM patient management. Insights from the literature review were supplemented with expert clinical opinion to develop six working packages (WPs), each coordinated by one member of the SC (outlined in [Table 1](#)) with draft consensus statements included in the toolbox. The final member panel (including the SC members) consisted of 35 experts (including 2 individuals who did not participate in the voting of consensus recommendations). The following modified Delphi process was used for preparation, consensus, and reporting between 21 May 2021 and 30 June 2021.

Table 1. Overview of working packages and main statements		
Working package	Questions	Statements
COVID-19 diagnosis, treatment, and mitigation strategies (Coordinator: M. von Liliefeld-Toal)	What are efficient strategies to prevent SARS-CoV-2 infection?	STATEMENT 1: Patients, persons in their close relationship, and caregivers must apply common preventive strategies such as: hygiene measures, physical distancing, wearing facial masks, and staying, if possible, in single bedrooms. Efforts in the reorganization of hematology units with telehealth to reduce clinic visits, regular SARS-CoV-2 swab testing and vaccination of health care personnel, of persons in close relationship to patients and caregivers are to be favored.
	Are anti-COVID-19 vaccines indicated in HM patients to prevent SARS-CoV-2 infection?	STATEMENT 2: Vaccination is strongly recommended. Whenever possible, vaccination should be proposed before initiation of treatment. If this is not possible, vaccines can be administered any time during disease course or any therapy in principle. In the case an urgent treatment is required, withholding the planned therapy for receiving vaccines is not justified. To note, immune response might be severely reduced in those receiving B-cell depleting agents.
	Are current available vaccines safe in HMs?	STATEMENT 3: The benefits of vaccination far outweigh the risks of vaccine-related adverse events and given the greater severity of the disease and higher risk of death, HM patients are considered a high-priority subgroup for SARS-CoV-2 vaccination.
	Who should be tested for SARS-CoV-2 at what time?	STATEMENT 4: Diagnostic testing is mandatory at presentation of any COVID-19 symptoms and after COVID-19 diagnosis until receiving two negative results, even after receiving vaccination against SARS-CoV-2. We recommend screening all asymptomatic patients for SARS-CoV-2 at admission for in-hospital stay, 2-3 days later, and then following local policy. Concerning outpatient clinic visits, we encourage developing local policies according to local risk and recommend testing in the case of high SARS-CoV-2 incidence in the community.
	What type of test should be used with which material?	STATEMENT 5: NAT (nucleic acid amplification technique) testing is preferred, usually using RT-PCR as the most sensitive method. Material from the respiratory tract should be used, swabs are preferred but spit tests, throat gargles, sputum and nasopharyngeal aspirates are also under investigation. The evaluation of serum neutralizing antibodies for detecting immune response after exposure to SARS-CoV-2 is encouraged, when feasible.
HM treatment in the COVID-19 pandemic (Coordinator: J. Gribben)	With the aim to reduce hospital visits and stay during the pandemic, how is it possible to apply imaging techniques to efficiently stage and restage HM patients?	STATEMENT 6: A cancer care prioritization and treatment intensity approach has been adapted for HM patients during the pandemic. HM patients, deemed appropriate for treatment because of their high-risk disease, should be imaged as needed and as closely as possible to pre-pandemic levels. Imaging in HM patients with low-risk disease should be restricted to that level which is necessary to assess their clinical risk status.
	Should fertility preservation facilities be guaranteed during the SARS-CoV-2 pandemic?	STATEMENT 7: Fertility preservation facilities should be offered wherever possible, particularly in young patients before undergoing intensive chemotherapy. The decision must consider the availability and accessibility of the local facilities.
	Are there different indications/thresholds for growth factor support (granulocyte-colony stimulating factors or erythropoietin stimulating agents) or immunoglobulin replacement during the SARS-CoV-2 pandemic?	STATEMENT 8: To lower the risk of febrile neutropenia, consider extending the indication of granulocyte colony-stimulating factor (G-CSF) for patients with intermediate (10%-20%) and high risk for febrile neutropenia (>20%), and specifically for elderly patients with comorbidities. Immunoglobulin replacement, administration of which should be carefully weighed against the risk of additional hospital visits, can be used favorably by subcutaneous application.
	Should the prevention and management of thromboembolic events be different in HM patient with SARS-CoV-2?	STATEMENT 9: In HM patients with SARS-CoV-2 infection, there is an increased risk of thromboembolic events and associated complications such as lung vessel obstructive thrombo-inflammatory syndrome. Prophylaxis using low molecular weight heparin (LMWH) is recommended for inpatients.
	When can a SARS-CoV-2 infected HM patient be considered cured and be rechallenged with anticancer treatments?	STATEMENT 10: There is no clear definition of the time point when HM patients can be considered healed from COVID-19. The decision to rechallenge anticancer treatment in the absence of symptoms of active viral infection should be individualized. Doctors may consider the time elapsed since the beginning of SARS-CoV-2 infection, sequential negative PCR tests, the presence of neutralizing antibodies, the type and risk of HM, and the treatment to be administered.
During the SARS-CoV-2 pandemic, has the risk/benefit balance for including an individual patient in a clinical trial changed?	STATEMENT 11: Even in the SARS-CoV-2 pandemic, participation in appropriate clinical trials should be pursued for HM patients. The risk/benefit balance for including an individual patient in a clinical trial is determined by multiple factors such as the R0 index and caseload of the pandemic, health care organization characteristics, and resources, as well as the nature of the interventional study. Telemedicine or local testing should be encouraged in this setting.	
HM management in the COVID-19 pandemic: lymphoma including CLL (Coordinator: L. Arcaini)	When should we initiate lymphoma treatment in the COVID-19 pandemic? Indolent versus aggressive lymphoma	STATEMENT 12: In indolent lymphomas, including CLL and WM, 'watch and wait' is the recommended strategy for asymptomatic patients with low tumor burden. When treatment is indicated according to consensus guidelines, treatment should be administered. In unvaccinated patients, however, treatment deferral after anti-SARS-CoV-2 vaccination should be considered in the absence of an urgent treatment indication.  In newly diagnosed or relapsing aggressive lymphoma, patients should be treated according to guidelines and a general delay of treatment initiation is not recommended. In unvaccinated patients, in the absence of urgent treatment indication, however, an individual treatment deferral after anti-SARS-CoV-2 vaccination (at least one injection) may be considered. Whenever possible, patients with

Continued

Table 1. Continued		
Working package	Questions	Statements
	<p>Should we modify lymphoma treatment in the COVID-19 pandemic? In indolent lymphoma/CLL/WM, first line, maintenance, relapse</p> <p>Should we modify lymphoma treatment in the COVID-19 pandemic? In first-line aggressive lymphoma (DLBCL, MCL, PTCL) and HL?</p> <p>Should we modify lymphoma treatment in the COVID-19 pandemic? In relapsed aggressive lymphoma (DLBCL, MCL, PTCL) and HL? Should autologous, allogeneic SCT or CAR-T cell therapy be postponed in the pandemic?</p> <p>How to treat lymphoma in the case of SARS-CoV-2 positive asymptomatic or oligosymptomatic patients? All histological types, at diagnosis, or during therapy</p>	<p>lymphoma should be vaccinated against SARS-CoV-2 before the initiation of therapy. In the absence of an urgent treatment indication, a congruous interval (up to 4 weeks) before an anti-CD20 antibody-containing regimen should be respected.</p> <p>STATEMENT 13: If treatment is necessary in indolent lymphoma, less immunosuppressive therapies (e.g. therapies avoiding anti-CD20 antibodies in CLL and anti-CD20 maintenance in follicular lymphoma) and treatments with less need for hospital stays, without compromising efficacy, are recommended. Vaccination before start of treatment is recommended.</p> <p>STATEMENT 14: For aggressive lymphoma in the curative setting patients should be treated according to consensus guidelines without compromising efficacy of treatment. If treatment options are equivalent, less immunosuppressive therapies and treatment with less need for hospital stays are recommended.</p> <p>STATEMENT 15: In the curative setting patients with relapsed aggressive lymphoma should be treated according to consensus guidelines without compromising efficacy of treatment. If treatment options are equivalent or patients are in a non-curative situation, less immunosuppressive treatments with less need for hospital stays are recommended. Patients with refractory and/or relapsed DLBCL, PTCL, and HL who are eligible to autologous, allogeneic SCT or CAR-T cell therapy should first receive salvage regimens. HDT/ASCT or CAR-T cell therapy should be considered in eligible patients with DLBCL and MCL. Delaying (or omitting) consolidative autologous SCT in PTCL patients in CR following induction therapy may be considered, as its role is still controversial.</p> <p>STATEMENT 16: All positive cases should be investigated with lung computed tomography scan. In indolent lymphomas, if possible, defer commencement of treatment until nasopharyngeal swab negativity and resolution of clinical symptoms. If already on treatment the decision to continue or stop treatment should be based on the nature of the treatment and the severity of COVID-19.</p>
<p>HM management in the COVID-19 pandemic: MM (Coordinator: M. Dimopoulos)</p>	<p>When is it mandatory to initiate myeloma treatment during the COVID-19 pandemic?</p> <p>How to treat myeloma in the case of SARS-CoV-2-positive asymptomatic or oligosymptomatic patients?</p> <p>Should first-line myeloma treatment be adapted in the COVID-19 pandemic for transplant eligible/ineligible patients?</p> <p>Should recommendations for maintenance therapy be changed in the COVID-19 pandemic?</p> <p>Should treatment of relapsed myeloma be changed in the COVID-19 pandemic? Transplant eligible/non-eligible</p> <p>Are cellular therapies such as ASCT or CAR-T cells to be postponed in the pandemic?</p>	<p>STATEMENT 17: Treatment should not be delayed for newly diagnosed MM patients with active disease, as well as in cases of myeloma medical emergencies. Although patients with established CRAB criteria should start treatment as soon as possible, MM patients presenting with one lesion or SLiM-only criteria may delay treatment only for a limited time period in cases of extreme COVID-19 dissemination in the community. Depending on the local incidence of COVID-19, patients with a solitary plasmacytoma as the sole indication for treatment may only receive local radiotherapy initially. Patients with a diagnosis of monoclonal gammopathy of undetermined significance or smoldering MM are typically in long-term monitoring of their disease status.</p> <p>STATEMENT 18: In cases of MM patients with a positive PCR test for SARS-CoV-2, but with no symptoms of COVID-19, a 14-day quarantine should be considered if myeloma-related events allow the delay of treatment. Otherwise, treatment should be given with very close monitoring of symptoms for early detection of COVID-19 progression. If the patient has symptomatic COVID-19, antimyeloma treatment should be delayed until total clinical recovery from COVID-19.</p> <p>STATEMENT 19: The combination of bortezomib and dexamethasone with lenalidomide (VRd) or thalidomide (VTD), as well as the combination of daratumumab with VTD (DaraVTD) is the most preferred induction therapy for transplant eligible patients with possible modifications for patients with sufficient response. Patients with high-risk disease features may receive ASCT, which could be postponed in patients with standard-risk disease, depending on the epidemiology of COVID-19 in the community, but not more than 3 months, if possible. For transplant ineligible patients, the indicated regimens include VRd or daratumumab-based therapies (DaraRd or DaraVMP). In cases of high incidence of COVID-19 in the community, an all-oral regimen such as Rd could be implemented and the addition of bortezomib or daratumumab could be made later or upon insufficient response. In general, patient visits to the hospital should be minimized, by e.g. de-intensification of treatment in responding patients, if treatment outcome is not compromised.</p> <p>STATEMENT 20: Patients with MM who are in the maintenance phase of their treatment should continue with their oral therapy and reduce visits to the clinic. Subcutaneous bortezomib administration for high-risk patients might be self-administered at home, if feasible, to avoid omission or delay of treatment and to minimize visits to the hospital.</p> <p>STATEMENT 21: Patients with symptomatic relapse should not delay treatment. All oral regimens with equivalent efficacy should be preferred over regimens necessitating frequent hospital visits. Alternatively, less intensive dosing schedules of intravenous and subcutaneous drugs should be implemented, such as weekly administration of proteasome inhibitors and rapid infusions of monoclonal antibodies. Salvage transplant can be avoided during the COVID-19 pandemic.</p> <p>STATEMENT 22: Patients with standard-risk MM may delay upfront ASCT in communities with high incidence of COVID-19, whereas those with high-risk MM may proceed. Patients eligible for a clinical trial with CAR-T cells without alternative treatment options can proceed as well. In this situation and in cases where ASCT or the CAR-T cell procedure cannot be postponed according to physician's discretion,</p>

Continued

Table 1. Continued		
Working package	Questions	Statements
HM management in the Covid-19 pandemic: AML/MDS/ALL (Coordinator: G. Sanz)	Should any modification to standard of care treatment of MDS during the COVID-19 pandemic be implemented?	exclusion of COVID-19 by PCR for SARS-CoV-2 is deemed necessary, along with strict precautions to prevent SARS-CoV-2 transmission in the transplant department. STATEMENT 23: A risk-adapted treatment strategy based on patient's condition, therapeutic goals, and individual risk by IPSS-R should be adopted also in the pandemic.
	Should any modification to standard of care treatment of AML be implemented during the COVID-19 pandemic?	STATEMENT 24: Intensive chemotherapy should be offered without delay for eligible patients both at diagnosis and relapse. Low-intensity therapies (i.e. hypomethylating agent +/- venetoclax) might be preferable for older (>65 years of age) and/or unfit patients. For consolidation, the use of intermediate-dose cytarabine and/or reducing the number of cycles could be considered. Treatment of acute promyelocytic leukemia should not be modified.
	Should any modification to standard of care treatment of ALL during the COVID-19 pandemic be implemented?	STATEMENT 25: During the COVID-19 pandemic initial induction, intensive post-remission therapy and maintenance therapy of ALL should be given with as few modifications as possible in children, adolescents, and young adults, as well as in adult patients. All phases of therapy and second-line treatments for refractory/relapsed patients should be started without delay. For Ph+ ALL a chemotherapy-free approach should be considered.
	Should standard of care treatment be modified or stopped in a SARS-CoV-2-positive MDS, AML, blast phase of MPN/CML, ALL patient with asymptomatic or mild COVID-19 disease?	STATEMENT 26: Decisions about administering AML-, ALL-, and MDS-directed therapy in patients with asymptomatic or mild COVID-19 should consider the indication for treatment, goals of care, treatment intensity, and patient's history of tolerance to treatment. Delaying treatment until at least 2 weeks after resolution of symptoms and SARS-CoV-2 PCR negativity is recommended whenever possible.
HM management in the COVID-19 pandemic: MPN/CML (Coordinator: D. Rea)	Should the standard of care treatment be modified or stopped in a SARS-CoV-2-positive patient with AML, blast phase of MPN/CML, ALL, or MDS and severe COVID-19 disease?	STATEMENT 27: All AML, ALL, and MDS patients should interrupt any active treatment of his/her hematological malignancy and receive the best available therapy for COVID-19 along with the best supportive care for HM.
	Should allogeneic hematopoietic cell transplantation for patients with AML, blast phase of MPN/CML, ALL, or MDS be postponed, or conditioning regimen modified during the pandemic?	STATEMENT 28: Allogeneic HSCT is a curative treatment approach for patients with MDS, AML, and ALL. If indicated, a deferral of the HSCT or modification of the planned conditioning regimen is not justified but can be considered on a case-by-case basis. In case of COVID-19 hot spot regions and/or lack of intensive care unit beds, transferring the patient to other centers should be considered.
	How to treat MPN or CML in case of asymptomatic or mild/moderate symptomatic COVID-19?	STATEMENT 29: In case of asymptomatic or mild/moderate COVID-19, newly diagnosed CML patients should initiate CML treatment without modifications; moreover, there is no indication to interrupt or modify TKI therapy in previously diagnosed CML patients on continuous drug treatment. Likewise, therapy for MPN should not be adjusted in this situation.
	How to treat MPN or CML in the case of COVID-19 requiring hospitalization (severe or very severe)?	STATEMENT 30: Treatment initiation in newly diagnosed CML with severe/critical COVID-19 disease should be evaluated on a case-by-case basis, considering the urgency of remission induction. In case of previously diagnosed CML patients, there is no indication to systematically interrupt or modify TKI therapy. Attention should be paid to the impact of potential TKI/anti-COVID-19 drug-drug interactions. In MPNs, particular attention should be paid to patients receiving ruxolitinib. Otherwise, therapies such as anticoagulants or cytoreductive therapy may need to be adjusted depending upon the patient's individual clinical scenario.
HM management in the COVID-19 pandemic: MPN/CML (Coordinator: D. Rea)	Is there any indication to change the current approach to SARS-CoV-2-negative CML patients during the COVID-19 pandemic?	STATEMENT 31: The general approach to CML patients does not require major modifications in the pandemic, whereas monitoring and supportive care need careful planning to guarantee safe outpatient treatment of CML patients. Home delivery and telemedicine should be encouraged.
	Is there any indication to change the current approach to MPN patients during the COVID-19 pandemic?	STATEMENT 32: The general approach to MPN patients does not require modifications due to the COVID-19 pandemic, whereas monitoring and supportive care need careful planning to guarantee safe treatment of MPN patients outside the hospital setting. Home delivery and telemedicine should be encouraged.
	Is SCT to be postponed for MPN/CML patients during the pandemic?	STATEMENT 33: HSCT should not be postponed for MPN/CML patients with strong indication for HSCT, while measures should be taken to guarantee post-HSCT treatment, monitoring, and care for patients who acquire SARS-CoV-2 after HSCT.

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ASCT, autologous stem cell transplantation; CAR-T, chimeric antigen receptor T-cell; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CR, complete remission; CRAB, end-organ damage due to hypercalcemia, renal failure, anemia and bone lesions; DaraRd, daratumumab, lenalidomide, dexamethasone; DaraVMp, daratumumab, bortezomib, melphalan, prednisone; DLBCL, diffuse large B-cell lymphoma; HDT, high-dose therapy; HM, hematological malignancy; HSCT, hematopoietic stem cell transplantation; IPSS-R, revised International Prognostic Scoring System; MCL, mantle cell lymphoma; MDS, myelodysplastic syndromes; MPN, myeloproliferative neoplasm; Ph, Philadelphia chromosome; PTCL, peripheral T-cell lymphoma; Rd, lenalidomide, dexamethasone; SCT, stem cell transplantation; SLiM, sixty percent bone marrow plasma cells; involved:uninvolved serum free light chain ratio  $\geq 100$ ;  $>1$  focal lesions on MRI studies; TKI, tyrosine-kinase inhibitor; WM, Waldenström's macroglobulinemia.

Background information including the WPs along with the statements were sent to panelists for their structured feedback (agree, disagree, abstain, with comments). The SC incorporated all comments and suggestions, with discussion of all disagreements, resulting in a revised set of WP statements that were then sent for a second anonymous vote to all panelists. Consensus was considered to be reached if agreement was recorded by >75% of panelists. Lack of agreement on a statement would elicit revision and a third voting round, resulting in either consensus or final rejection of the statement.

## RESULTS: CLINICAL QUESTIONS AND STATEMENTS

### *WP1: COVID-19 diagnosis, treatment, and mitigation strategies*

**What are efficient strategies to prevent SARS-CoV-2 infection?**

**STATEMENT 1:** Patients, persons in their close relationship, and caregivers must apply common preventive strategies such as: hygiene measures, physical distancing, wearing facial masks, and staying, if possible, in single bedrooms. Efforts in the reorganization of hematology units with telehealth to reduce clinic visits, regular SARS-CoV-2 swab testing, and vaccination of health care personnel, of persons in a close relationship to patients and caregivers are to be favored.

There are several studies indicating efficacy of preventing strategies such as keeping distance, using face masks, and implementing quarantine and isolation in the control of SARS-CoV-2 transmission and thereby disease burden.<sup>33-39</sup> Reorganization of clinic visits and management of hematology units to reduce the risk of transmission have been reported by many to be feasible.<sup>40-42</sup> Measures may include, but are not limited to implementing telehealth, defining dedicated areas and teams for care of HM patients and screening of the staff. This needs to be adapted, however, to local strategies and policies. There is evidence to support the efficacy of vaccinating household members and caregivers derived from studies on vaccination of staff in nursing homes.<sup>43</sup>

**Final voting: agree 100%, disagree 0% (0/33).**

**Are anti COVID-19 vaccines indicated in HM patients to prevent SARS-CoV-2 infection?**

**STATEMENT 2:** Vaccination is strongly recommended. Whenever possible, vaccination should be proposed before initiation of treatment. If this is not possible, vaccines can be administered any time during disease course or any therapy in principle. In the case that an urgent treatment is required, withholding the planned therapy for receiving vaccines is not justified. To note, immune response might be severely reduced in those receiving B-cell-depleting agents.

Currently, there are efficient vaccines for immunocompetent individuals, licensed against COVID-19.<sup>44-46</sup> Generally, vaccines work in patients with HMs with immune<sup>47</sup> and clinical responses<sup>48-50</sup> and are currently generally recommended.<sup>51-53</sup> By consequence, one can assume that vaccination against SARS-CoV-2 might be effective in HMs,<sup>54</sup> however, these immunocompromised patients have not been included in the registration clinical trials. Reports on anti-SARS-CoV-2 vaccine efficacy in HMs disclosed a lower humoral immune response compared with that obtained in the healthy population.<sup>14-32</sup> In addition, HM patients receiving B-cell-depleting therapy, anti-CD38 monoclonal antibodies, and JAK inhibitors are at higher risk of failing seroconversion after SARS-CoV-2 vaccines.<sup>14-32</sup> Concerning HSCT, many patients will lose their immunity following transplantation, but can generally begin to be vaccinated around 3 months after the procedure. In consideration of the potential ineffectiveness of the immune system, HM patients should be tested for seroconversion after SARS-CoV-2 vaccines and should maintain all the protective measures. There is no rationale to stop ongoing therapy prevaccination, since side-effects are not influenced by concurrent HM treatment.<sup>55</sup>

**Final voting: agree 96.97%, disagree 3.03% (1/33).**

**Are current available vaccines safe in HMs?**

**STATEMENT 3:** The benefits of vaccination far outweigh the risks of vaccine-related adverse events and given the greater severity of the disease and higher risk of death, HM patients are considered a high priority subgroup for SARS-CoV-2 vaccination.

Recent preliminary evidence in HMs showed that anti-SARS-CoV-2 vaccines are safe.<sup>14-32,55,56</sup> Rare cases of cerebral sinus vein thrombosis or splanchnic vein thrombosis after ChAdOx1 nCoV-19 and Ad26.COV2.S vaccination have been reported in individuals between the ages of 20 and 55 years.<sup>57-60</sup> More recently, some cases of myocarditis after COVID-19 messenger RNA vaccination have been described in younger cases.<sup>61</sup> The benefits of vaccination far outweigh vaccine-related risks, however, and vaccination is strongly recommended for patients with HMs.

**Final voting: agree 96.97%, abstain 3.03%, disagree 0% (0/33).**

**Who should be tested for SARS-CoV-2 at what time?**

**STATEMENT 4:** Diagnostic testing is mandatory at presentation of any COVID-19 symptoms and after COVID-19 diagnosis until receiving two negative results, even after receiving vaccination against SARS-CoV-2. We recommend screening all asymptomatic patients for SARS-CoV-2 at admission for in-hospital stay, 2-3 days later, and then following local policy. Concerning outpatient clinic visits, we encourage developing local policies according to local risk and recommend testing in the case of high SARS-CoV-2 incidence in the community.

As there is clear evidence that patients with asymptomatic COVID-19 may spread the virus in any facility, screening of patients admitted for an in-hospital stay is the first and foremost step to keep care facilities COVID-free areas.<sup>62</sup> Testing at presentation of symptoms should be carried out in all HM patients regardless of their current disease status and therapy. Following several reports on prolonged viral shedding, especially in patients with severe course of the disease and those with low numbers of B cells,<sup>63-65</sup> it should be considered to carry out follow-up tests until negative results are confirmed before admission to the care units. Viability of SARS-CoV-2 can only be proven by viral culture, but this is not routinely recommended. Therefore, the interpretation of a positive detection should be carefully examined. Some institutions carry out screening in the outpatient clinic during phases of high incidence in their community. This is a feasible strategy to avoid spread amongst those patients whose treatment cannot be deferred. In the setting of acute leukemias, PCR testing before every chemotherapy cycle is strongly recommended.

**Final voting: agree 93.94%, disagree 6.06% (2/33).**

**What type of test should be used with which material?**

**STATEMENT 5: Nucleic acid amplification technique (NAT) testing is preferred, usually using RT-PCR as the most sensitive method. Material from the respiratory tract should be used, swabs are preferred but spit tests, throat gargles, sputum and naso-pharyngeal aspirates are also under investigation. The evaluation of serum neutralizing antibodies for detecting immune response after exposure to SARS-CoV-2 is encouraged, when feasible.**

The current gold standard and most widely used assays for the diagnosis of SARS-CoV-2 infection are based on RT-PCR and reported on the web at <https://www.360dx.com/coronavirus-test-tracker-launched-covid-19-tests>. Target genes tested include RNA-dependent RNA polymerase (RdRp), open reading frame (ORF1), envelope (E), and nucleocapsid (N) genes of the SARS-CoV-2 genome. False-negative results may be due to improper sampling, degradation of the viral RNA during shipping/storage, low viral loads, incorrect nucleic acid extraction, presence of amplification inhibitors, and mutations in the RT-PCR target region. A false positive is mostly due to sample cross contamination. To note, in long lasting positive tests,<sup>66</sup> viability of SARS-CoV-2 can only be proven by viral culture, however, this is not recommended routinely. NAT is preferred over antigen testing to diagnose SARS-CoV-2 infection, because of higher sensitivity. In fact, the sensitivity of antigen tests may drop down to 50% in asymptomatic cases, which does not make them a reliable tool for the diagnosis of infection, especially in HMs.<sup>67-72</sup> Most centers use swabs for detecting SARS-CoV-2 RNA, but alternative clinical samples, like saliva or sputum, may also provide reliable results and reduce contact between health care personnel and infected individuals. It seems

that the best results, however, can be expected from nasopharyngeal swabs or saliva.<sup>73-77</sup> The evaluation of serum neutralizing antibodies for detecting immune response after exposure to SARS-CoV-2 is encouraged, and in HM, a lower rate of seroconversion is expected as estimated at 69%.<sup>12</sup>

**Final voting: agree 90.91%, abstain 9.09%, disagree 0% (0/33).**

### **WP2: HM treatment in the COVID-19 pandemic**

**With the aim to reduce hospital visits and stay during the pandemic, how is it possible to apply imaging techniques to efficiently stage and restage HM patients?**

**STATEMENT 6: A cancer care prioritization and treatment intensity approach has been adapted for HM patients during the pandemic. HM patients, deemed appropriate for treatment because of their high-risk disease, should be imaged as needed and as closely as possible to pre-pandemic levels. Imaging in HM patients with low-risk disease should be restricted to that level which is necessary to assess their clinical risk status.**

For HMs in the curative setting, the risk-benefit balance during the SARS-CoV-2 pandemic clearly favors maintaining established treatment guidelines, and multidisciplinary discussions should recommend standard imaging. In HM patients with low-risk disease, imaging should be restricted to that necessary to assess clinical risk status. To note, imaging resources may be limited during the pandemic for monitoring COVID-19 patients. Finally, a careful scheduling of imaging may avoid unnecessary hospital visits.

**Final voting: agree 100%, disagree 0% (0/33).**

**Should fertility preservation facilities be guaranteed during the SARS-CoV-2 pandemic?**

**STATEMENT 7: Fertility preservation facilities should be offered wherever possible, particularly in young patients before undergoing intensive chemotherapy. The decision must consider the availability and accessibility of the local facilities.**

While hematologists should continue to discuss fertility issue with patients to maximize the likelihood of a successful pregnancy after chemotherapy regimens, the possibility to offer fertility preservation during the pandemic may be compromised by limited facility availability. Depending on patients' preferences, less intensive regimens [e.g. ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) instead of escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) for patients with Hodgkin's lymphoma (HL)] may be an option when semen or oocyte/ovarian tissue cryopreservation is not feasible.

**Final voting: agree 90.91%, disagree 9.09% (3/33).**



**Are there different indications/thresholds for growth factor support (granulocyte colony-stimulating factors or erythropoietin-stimulating agents) or immunoglobulin replacement during the SARS-CoV-2 pandemic?**

**STATEMENT 8:** To lower the risk of febrile neutropenia, consider extending the indication of granulocyte colony-stimulating factor (G-CSF) for patients with intermediate (10%-20%) and high risk for febrile neutropenia (>20%), and specifically for elderly patients with comorbidities. Immunoglobulin (Ig) replacement, administration of which should be carefully weighed against the risk of additional hospital visits, can be used, favorably by SC application.

Most systemic therapies used in high-risk HM are associated with a significant risk of immunosuppression. Therefore, relevant supportive measures should be implemented such as prophylactic use of hematopoietic growth factors in all regimens with a medium/high risk of immunosuppression.<sup>78</sup> Moreover, to lower the risk of febrile neutropenia, the indication for G-CSF can be extended. The theoretical concern raised of acute respiratory failure due to G-CSF-induced leukocyte recovery in patients with a pulmonary infection due to SARS-CoV-2 does not outweigh the benefit, but G-CSF should be applied with caution.<sup>79</sup> The use of erythropoietin, within guidelines indication, can be considered to prevent patients' visits for blood transfusion. After careful review and confirmation of the indication, Ig should be maintained where possible to avoid further infectious complications. If available, subcutaneous formulations can be a useful alternative and avoid prolonged hospital stays and unnecessary visits.

**Final voting: agree 96.97%, disagree 3.03% (1/33).**

**Should the prevention and management of thromboembolic events be different in HM patients with SARS-CoV-2?**

**STATEMENT 9:** In HM patients with SARS-CoV-2 infection, there is an increased risk of thromboembolic events and associated complications such as lung vessel obstructive thrombo-inflammatory syndrome. For hospitalized patients, prophylaxis using low molecular weight heparin (LMWH) is recommended for SARS-CoV-2-infected patients.

There are a number of hemostatic alterations associated with SARS-CoV-2.<sup>80,81</sup> In HM patients, prophylaxis of thromboembolic events should be continued according to existing guidelines. Patients should receive careful monitoring as routinely as possible to prevent possible bleeding complications. Patients hospitalized with a confirmed diagnosis of COVID-19 should receive prophylaxis of thromboembolic events using LMWH or fondaparinux, or even unfractionated heparin, if critically ill with a significantly reduced kidney function. When direct oral anticoagulants are used as prophylaxis, possible drug interactions with medications that are tested for use against SARS-CoV-2 must be considered and reviewed by pharmacists. The role of full therapeutic anticoagulation in severely ill patients with SARS-CoV-2 remains controversial.

**Final voting: agree 93.94%, disagree 6.06% (2/33).**

**When can a SARS-CoV-2-infected HM patient be considered cured and be rechallenged with anticancer treatments?**

**STATEMENT 10:** There is no clear definition of the time point when HM patients can be considered healed from COVID-19. The decision to rechallenge anticancer treatment in the absence of symptoms of active viral infection should be individualized. Doctors may consider the time elapsed since the beginning of SARS-CoV-2 infection, sequential negative PCR tests, the presence of neutralizing antibodies, the type and risk of HM, and the treatment to be administered.

Initially, two negative PCR tests more than 24 h apart were required to confirm cure of SARS-CoV-2 infection. To note, many HM patients have positive PCR tests for prolonged periods without active infection.<sup>66</sup> Studies on the associations between swab test result, number of cycle thresholds, viral loads, viral cultures and disease status and infectivity, however, did not include significant numbers of severely immunosuppressed patients or patients with HM<sup>82,83</sup> and therefore these data cannot be considered final. Viral persistence, reactivation, or reinfection with novel variants of SARS-CoV-2 is a potential risk for the patients resuming therapy, and for other HM patients in the same wards and outpatient clinics. There are a number of reports of prolonged infections in immunosuppressed patients, especially if receiving corticosteroids, intensive treatments, and anti-CD20 monoclonal antibodies.<sup>84,85</sup> The decision to rechallenge with anticancer therapy should consider the type of treatment being proposed, since there is a suggestion that some targeted therapies<sup>20-23</sup> are relatively safe even during SARS-CoV-2 infection, whereas immunochemotherapy poses bigger risks.

**Final voting: agree 93.94%, abstain 6.06%, disagree 0% (0/33).**

**During the SARS-CoV-2 pandemic, has the risk/benefit balance for including an individual patient in a clinical trial changed?**

**STATEMENT 11:** Even in the SARS-CoV-2 pandemic, participation in appropriate clinical trials should be pursued for HM patients. The risk/benefit balance for including an individual patient in a clinical trial is determined, however, by multiple factors such as the R0 index and caseload of the pandemic, health care organization characteristics and resources, as well as the nature of the interventional study. Telemedicine or local testing should be encouraged in this setting.

In many instances, clinical trials represent the best possible chance of a successful outcome for HM patients. Trials with a high probability to need inpatient care, intensive care facilities, and in areas with high incidence of SARS-CoV-2 infection can be temporarily considered of lower priority and deferred during the pandemic. Therefore, depending on

the level of resources available for clinical trial activities, doctors should prioritize interventional studies with the following characteristics: (i) trials with drugs with expected high likelihood of benefit (e.g. very promising activity in early-phase or molecularly-selected therapy), (ii) trials with experimental drugs supposed to be safer than the standard of care, (iii) trials with low intensity treatment, and (iv) trials in diseases or conditions without an effective standard of care. During the SARS-CoV-2 pandemic, deviations from clinical trial protocols have very often been unavoidable. Treating physicians should remain as close as possible within the provisions of clinical trial protocols, however, so that the risk/benefit balance of the clinical trial remains acceptable.

**Final voting: agree 93.94%, abstain 6.06%, disagree 0% (0/33).**

### **WP3: HM management in the COVID-19 pandemic: lymphoma including CLL**

**When should we initiate lymphoma treatment in the COVID-19 pandemic? Indolent versus aggressive lymphoma**

**STATEMENT 12: In indolent lymphomas, including CLL and Waldenstrom's macroglobulinemia (WM), 'watch and wait' is the recommended strategy for asymptomatic patients with low tumor burden. When treatment is indicated according to consensus guidelines, treatment should be administered. In unvaccinated patients, however, treatment deferral after anti-SARS-CoV-2 vaccination should be considered in the absence of an urgent treatment indication.**

**In newly diagnosed or relapsing aggressive lymphoma, patients should be treated according to guidelines and a general delay of treatment initiation is not recommended. In unvaccinated patients, however, in the absence of urgent treatment indication, an individual treatment deferral after anti-SARS-CoV-2 vaccination (at least one injection) may be considered. Whenever possible, patients with lymphoma should be vaccinated against SARS-CoV-2 before the initiation of therapy. In the absence of an urgent treatment indication, a congruous interval (up to 4 weeks) before an anti-CD20 antibody-containing regimen should be respected.**

Patients with lymphoma should be treated in highly specialized hematology centers in which general principles have been implemented to minimize the risk of COVID-19 spreading, such as repeat testing. For indolent lymphoma/CLL/WM requiring therapy, more flexibility in the initiation of therapy may be frequently explored. If indolent lymphoma requires therapy according to national consensus guidelines, however, then treatment should not be delayed. For aggressive lymphoma, delays in treatment initiation can result in significant worsening of the outcome.

**Final voting: agree 87.88%, abstain 12.12%, disagree 0% (0/33).**

**Should we modify lymphoma treatment in the COVID-19 pandemic? In indolent lymphoma/CLL/WM, first line, maintenance, relapse**

**STATEMENT 13: If treatment is necessary in indolent lymphoma, less immunosuppressive therapies [e.g. therapies avoiding anti-CD20 antibodies in CLL and anti-CD20 maintenance in follicular lymphoma (FL)] and treatments with less need for hospital stays, without compromising efficacy are recommended. Vaccination before start of treatment is recommended.**

In indolent lymphoma with limited disease, if treatment is indicated, a radiotherapy approach is encouraged according to established guidelines. When treatment is necessary, the type of therapy should be decided based on the most effective treatment and, only if with comparable efficacy, one should consider the less immunosuppressive alternative. Accordingly, if feasible, outpatient management with oral drugs may be preferred, limiting the access and length of stay in hospital. For patients with advanced FL, monotherapy with rituximab, rituximab + lenalidomide (if available) or less intensive immunochemotherapy, or R/O-CVP (rituximab/obinutuzumab, cyclophosphamide, vincristine, prednisone) should be considered. In first line, immunosuppressive approaches (i.e. bendamustine) should be avoided if possible and R/O-CVP or R/O-CHOP (combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone) are preferred over bendamustine-R/O because of their lower immunosuppressive potential. Fludarabine-based regimens (fludarabine, cyclophosphamide, and rituximab) should be avoided.

The risk of immunosuppression related to maintenance has to be considered and discussed with the individual patient. The decision to start or continue maintenance treatment with anti-CD20 may be considered according to the local epidemiological situation and vaccination status.

In the relapsed/refractory setting, if feasible, outpatient management with oral drugs should be considered with limited access to the hospital and drugs including lenalidomide in FL patients should be considered.

In CLL, targeted oral therapies, especially BTK inhibitors or venetoclax, should be a preferred option over immunochemotherapy, if available, in both first line and refractory/relapse setting, according to the approval of each drug. The use of anti-CD20 antibodies in association with novel inhibitors should be carefully evaluated and postponed if possible.

**Final voting: agree 84.85%, abstain 9.09%, disagree 6.06% (2/33).**

**Should we modify lymphoma treatment in the COVID-19 pandemic? In first-line aggressive lymphoma (diffuse large B-cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma) and HL?**

**STATEMENT 14: For aggressive lymphoma in the curative setting, patients should be treated according to consensus**

**guidelines without compromising efficacy of treatment. If treatment options are equivalent, less immunosuppressive therapies and treatment with less need for hospital stays are recommended.**

Referral to COVID-free centers should be particularly considered for patients with aggressive lymphomas. R-CHOP is a standard of care also during the COVID-19 pandemic, due to its curative potential in diffuse large B-cell lymphoma (DLBCL). R-mini CHOP with G-CSF support can be considered for the elderly; regimens different from R-CHOP [for instance dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R)] may be individually considered in specific situations (e.g. primary mediastinal large B-cell lymphoma, double hit lymphoma). Addition of high-dose methotrexate and high-dose cytarabine and/or intrathecal methotrexate should have a clinical justification.

In patients with mantle cell lymphoma (MCL), high-dose therapy with autologous stem cell transplantation (HDT/ASCT) as first-line consolidation may be delayed depending on the local epidemiological situation. Differently from FL, rituximab maintenance should be considered due to the demonstrated improved survival. Subcutaneous (s.c.) rituximab is recommended to reduce the time spent in the clinic.

It is not recommended to delay therapy initiation for patients with peripheral T-cell lymphoma (PTCL) and HL. Regarding PTCL, CHOP +/- etoposide is indicated for most patients with PTCL, even in the COVID-19 pandemic. Etoposide may be omitted, however, in patients >60 years of age due to increased risk of myelotoxicity and no advantage in PFS in comparison with CHOP alone in this age group.

For patients with previously untreated high-grade 'double hit' or 'triple hit' B-cell lymphoma and primary mediastinal B-cell lymphoma, immunochemotherapy with DA-EPOCH-R remains a frontline option during the COVID-19 pandemic, as R-CHOP may be suboptimal in this patient group.

**Final voting: agree 96.97%, disagree 3.03% (1/33).**

**Should we modify lymphoma treatment in the COVID-19 pandemic? In relapsed aggressive lymphoma (DLBCL, MCL, PTCL) and HL? Should autologous, allogeneic SCT or chimeric antigen receptor T-cell therapy be postponed in the pandemic?**

**STATEMENT 15: In the curative setting, patients with relapsed aggressive lymphoma should be treated according to consensus guidelines without compromising efficacy of treatment. If treatment options are equivalent or patients are in a non-curative situation, less immunosuppressive treatments with less need for hospital stays are recommended. Patients with refractory and/or relapsed DLBCL, PTCL, and HL who are eligible to autologous, allogeneic SCT or chimeric antigen receptor T-cell (CAR-T cell) therapy should first receive salvage regimens. HDT/ASCT or CAR-T cell therapy should be considered in eligible patients with DLBCL and MCL. Delaying (or omitting) consolidative autologous SCT in PTCL patients in complete**

**remission following induction therapy may be considered, as its role is still controversial.**

A high risk of death in patients undergoing intensive chemotherapy treatment which causes profound cytopenia is expected. This includes treatments such as high-dose methotrexate, DHAP (cisplatin, cytarabine, dexamethasone), escalated BEACOPP, intensive autologous and allogeneic HSCT. Despite this, in DLBCL, ASCT should be carried out without delay if the procedure is considered.

**Final voting: agree 93.94%, abstain 6.06%, disagree 0% (0/33).**

**How to treat lymphoma in the case of SARS-CoV-2-positive asymptomatic or oligosymptomatic patients? All histological types, at diagnosis, or during therapy**

**STATEMENT 16: All positive cases should be investigated with lung computed tomography (CT) scan. In indolent lymphomas, if possible, defer commencement of treatment until nasopharyngeal swab negativity and resolution of clinical symptoms. If already on treatment the decision to continue or stop treatment should be based on the nature of the treatment and the severity of COVID-19.**

In all positive cases, a characterization of COVID-19 patients with a lung CT scan, SARS-CoV-2 PCR tests, and serology is indicated. In indolent lymphomas, including CLL and WM, if possible, defer commencement of treatment until nasopharyngeal swab negativity and resolution of clinical symptoms. If already on treatment and with mild symptoms, BTK inhibitor therapy in WM might be continued, given the risk of IgM rebound and constitutional symptoms upon withdrawal.<sup>86,87</sup> Therapy with other novel inhibitors might be continued in the presence of a mild form of the disease not requiring hospitalization. Targeted therapies should be withheld, in case of hospitalization and/or need of oxygen therapy, until recovery. They could be resumed if patients are asymptomatic for at least 48 h and at least 14 days after symptoms have started<sup>88</sup> and, if possible, after two consecutive negative RT-PCR tests collected each approximately 1 week apart. Monoclonal antibodies and/or chemotherapy should be withheld until full characterization of the COVID-19 infection is carried out and until the patient is asymptomatic for 48 h, at least 14 days after symptoms start and, if possible, until nasopharyngeal swab negativity.<sup>88</sup> If there is no immediate threat from lymphoma, consider delaying chemotherapy until nasopharyngeal swab negativity. In aggressive lymphoma, when feasible, it is better to delay the start of treatment without compromising treatment in a curative setting.

**Final voting: agree 93.94%, abstain 6.06%, disagree 0% (0/33).**

**WP4: HM management in the COVID-19 pandemic: MM**

**When is it mandatory to initiate myeloma treatment during the COVID-19 pandemic?**

**STATEMENT 17:** Treatment should not be delayed for newly diagnosed MM (NDMM) patients with active disease, as well as in cases of myeloma medical emergencies. Although patients with presence of end-organ damage due to hypercalcemia, renal failure, anemia and bone lesions (CRAB criteria) should start treatment as soon as possible, MM patients presenting with one lesion or SLiM-only criteria (Sixty percent bone marrow plasma cells; Involved:uninvolved serum free Light chain ratio  $\geq 100$ ;  $> 1$  focal lesions on MRI studies) may delay treatment only for a limited time period in cases of extreme COVID-19 dissemination in the community. Depending on the local incidence of COVID-19, patients with a solitary plasmacytoma as the sole indication for treatment may only receive local radiotherapy initially. Patients with a diagnosis of monoclonal gammopathy of undetermined significance (MGUS) or smoldering MM (SMM) are typically in long-term monitoring of their disease status.

Patients with NDMM with active disease should initiate treatment.<sup>89</sup> In the presence of SLiM criteria, treatment initiation might be delayed only for a limited time period in cases of high COVID-19 dissemination in the community. Treatment cannot be postponed in cases of myeloma emergencies.<sup>90</sup> Severe anemia, hypercalcemia, and renal failure may necessitate hospitalization and immediate initiation of antimyeloma treatment, along with supportive care.<sup>91</sup> Spinal cord compression may necessitate immediate initiation of radiotherapy and/or orthopedic decompensation.<sup>92-94</sup> Orthopedic treatment of impeding fractures and radiotherapy for palliation of pain unresponsive to analgesics should not be postponed.<sup>92,94</sup> Patients with a diagnosis of MGUS or SMM do not require immediate treatment. Scheduled visits of patients with stable disease can be safely delayed. Alternatively, blood examination in local laboratories and consultation via telemedicine is encouraged. It should be stressed that patients with high-risk disease should be carefully monitored for development of symptomatic disease requiring treatment.<sup>95</sup>

**Final voting: agree 96.97%, abstain 3.03%, disagree 0% (0/33).**

**How to treat myeloma in the case of SARS-CoV-2-positive asymptomatic or oligosymptomatic patients?**

**STATEMENT 18:** In cases of MM patients with a positive PCR test for SARS-CoV-2, but with no symptoms of COVID-19, a 14-day quarantine should be considered if myeloma-related events allow the delay of treatment. Otherwise, treatment should be given with very close monitoring of symptoms for early detection of COVID-19 progression. If the patient has symptomatic COVID-19, antimyeloma treatment should be delayed until total clinical recovery from COVID-19.

Patients with MM and COVID-19 should be treated as per standard guidelines starting from isolation measures. The immune deregulation due to both myeloma- and treatment-related factors may result in a prolonged viral shedding and, subsequently, positive PCR for SARS-CoV-2 for a prolonged

time period.<sup>64,84,90,96</sup> The management of MM in the era of COVID-19 is challenging.<sup>8,97</sup> Asymptomatic patients for COVID-19 should stay quarantined at home for at least 14 days, under close surveillance for detecting COVID-19-associated signs and symptoms, in cases where antimyeloma therapy can be delayed. In patients with acute renal failure or any myeloma-related condition that requires medical attention, treatment should be administered.<sup>90</sup> If antimyeloma treatment has been initiated, this might continue for patients with an asymptomatic COVID-19 and active myeloma [MM-related symptoms, new diagnosis, recent relapse, suboptimal response to treatment, e.g. less than very good partial response (VGPR)] with close monitoring of COVID-19-related symptoms. Steroids and drugs inducing lymphopenia could be de-intensified. Prophylactic G-CSF for the prevention of neutropenia should be considered.

Upon the emergence of symptomatic infection, treatment should be interrupted and the dose of steroids should be adjusted according to the treatment algorithm for COVID-19.<sup>98</sup> Although symptomatic patients with mild COVID-19 may stay at home, close surveillance for aggravating symptoms is necessary.<sup>90</sup> Upon such clinical suspicion, patient referral to a reference center for COVID-19 should not be delayed, because the clinical presentation may deteriorate rapidly and early intervention may be life-saving. For patients enrolled in a clinical trial, investigational agents should be interrupted until COVID-19 resolution and the reporting should abide with the corresponding guidelines.

**Final voting: agree 90.91%, abstain 9.09%, disagree 0% (0/33).**

**Should first-line myeloma treatment be adapted in the COVID-19 pandemic for transplant eligible/ineligible patients?**

**STATEMENT 19:** The combination of bortezomib and dexamethasone with lenalidomide (VRd) or thalidomide (VTD), as well as the combination of daratumumab with VTD (DaraVTD), is the most preferred induction therapy for transplant eligible patients with possible modifications for patients with sufficient response. Patients with high-risk disease features may receive ASCT, which could be postponed in patients with standard-risk disease, depending on the epidemiology of COVID-19 in the community, but not more than 3 months, if possible.

For transplant ineligible patients the indicated regimens include VRd or daratumumab-based therapies [DaraRd (daratumumab, lenalidomide, dexamethasone) or DaraVMP (daratumumab, bortezomib, melphalan, prednisone)]. In cases of high incidence of COVID-19 in the community, an all-oral regimen such as Rd could be implemented and the addition of bortezomib or daratumumab could be made later or upon insufficient response.

**In general, patient visits to the hospital should be minimized, by e.g. de-intensification of treatment in responding patients, if treatment outcome is not compromised.**

For transplant-eligible NDMM patients, induction treatment can be administered for an extended period for up to six to eight cycles.<sup>90</sup> The combination of bortezomib with lenalidomide or thalidomide and dexamethasone (VRd or VTD), as well as the combination of daratumumab with VTD (DaraVTD) represent the preferred induction therapy.<sup>99-102</sup> The treatment schedule can be modified, for patients with sufficient response. Patients with high-risk disease features may receive ASCT after six to eight induction cycles due to otherwise increased probability of progression. In view of the novel triplet (or quadruplet) upfront combinations for NDMM patients, the necessity of upfront ASCT has been challenged.<sup>103</sup> In this context and due to the anticipated immunosuppression following ASCT, it is recommended to postpone mobilization, stem cell harvest, conditioning, and ASCT, mainly in patients with standard-risk disease. Physicians may completely avoid ASCT in patients with marginal fitness due to age or comorbidities. Stem cell harvest without mobilization chemotherapy should be considered for patients receiving daratumumab and or lenalidomide-based induction in order to achieve a sufficient stem cell yield.<sup>104,105</sup> In this case, G-CSF-only mobilization with the potential addition of plerixafor should be considered in order to avoid the immunosuppressive effect of high-dose cyclophosphamide. In case of close contact with a person diagnosed with COVID-19, however, stem cell harvests and any transplant procedures should not be carried out within at least 14, and preferably 21, days from the last contact.

In transplant ineligible NDMM patients, treatment should be based on all-oral regimens, e.g. lenalidomide with dexamethasone (Rd), especially for unfit patients, whereas the addition of bortezomib or daratumumab can be considered for patients with high-risk disease, or for those without sufficient response to Rd.<sup>90,102</sup> For fit or intermediate-fit myeloma patients, Rd can be considered as a bridge for two to three cycles, in case the COVID-19 pandemic is at a peak in the hospital; otherwise, the approved VRd or daratumumab-based therapies (DaraRd or DaraVMP) should be considered. Dexamethasone should be reduced to 20 mg weekly, whereas de-escalation (or even interruption) should be considered for responding patients, especially after the completion of nine cycles of treatment. **Final voting: agree 90.91%, abstain 9.09%, disagree 0% (0/33).**

**Should recommendations for maintenance therapy be changed in the COVID-19 pandemic?**

**STATEMENT 20: Patients with MM who are in the maintenance phase of their treatment should continue with their oral therapy and reduce visits to the clinic. S.C. bortezomib administration for high-risk patients might be self-administered at home, if feasible, to avoid omission or delay of treatment and to minimize visits to the hospital.**

All oral regimens used for the maintenance phase of treatment can be safely administered in myeloma patients,

whereas disease monitoring and safety assessment can be easily carried out with telemedicine. Bortezomib injections for high-risk patients can be administered in extended time periods, such as monthly instead of every 2 weeks, or delayed until the decrease in COVID-19 burden in the community.

**Final voting: agree 93.94%, abstain 6.06%, disagree 0% (0/33).**

**Should treatment of relapsed myeloma be changed in the COVID-19 pandemic? Transplant eligible/non-eligible**

**STATEMENT 21: Patients with symptomatic relapse should not delay treatment. All oral regimens with equivalent efficacy should be preferred over regimens necessitating frequent hospital visits. Alternatively, less intensive dosing schedules of intravenous and s.c. drugs should be implemented, such as weekly administration of proteasome inhibitors and rapid infusions of monoclonal antibodies. Salvage transplant can be avoided during the COVID-19 pandemic.**

Depending on the COVID-19 circumstances in the community, watchful waiting may be considered for biochemical relapses, especially for patients with a slow and gradual increase in the paraprotein level. Patients with refractory disease, new onset of CRAB features, or those with a biochemical relapse and a history of aggressive relapse with rapid deterioration of the clinical presentation, however, should receive next-line treatment without delay.<sup>90</sup> Regarding the selection of treatment regimen, orally administered agents (ixazomib, lenalidomide, pomalidomide, panobinostat) should be considered based on logistics. Neutropenia due to lenalidomide or pomalidomide must be managed according to published recommendations.<sup>106</sup> Alternative therapeutic approaches are recommended instead of salvage HSCT or an allogeneic transplant. Should a patient with relapsed/refractory MM achieve sufficient response (e.g. VGPR or better), modifications in the treatment schedule are advisable (once weekly instead of twice weekly bortezomib/carfilzomib, monthly daratumumab infusions). Substitution of bortezomib or carfilzomib with ixazomib, in cases of VGPR or better, is not recommended, as it is not supported by clinical studies. There are no data for isatuximab once monthly and thus in cases of combination with pomalidomide and dexamethasone, in countries where the combination has been approved, the schedule of isatuximab administration has to remain unchanged (i.e. every 2 weeks).<sup>107</sup> Similarly, elotuzumab in combination with pomalidomide and dexamethasone should be given according to protocol.<sup>108</sup> Selinexor or belantamab mafodotin can be used in triple-class refractory patients.<sup>102,109,110</sup>

**Final voting: agree 84.85%, abstain 15.15%, disagree 0% (0/33).**

**Are cellular therapies such as ASCT or CAR-T cells to be postponed in the pandemic?**

**STATEMENT 22: Patients with standard-risk MM may delay upfront ASCT in communities with a high incidence of COVID-19, whereas those with high-risk MM may proceed. Patients eligible for a clinical trial with CAR-T cells without alternative treatment options can proceed as well. In this situation and in cases where ASCT or the CAR-T cell procedure cannot be postponed according to physician's discretion, exclusion of COVID-19 by PCR for SARS-CoV-2 is deemed necessary, along with strict precautions to prevent SARS-CoV-2 transmission in the transplant department.**

Both SCT and CAR-T cell therapy should be offered to all MM patients with anticipated survival benefit. Strict precautions to prevent SARS-CoV-2 transmission in transplant centers should be taken along with exclusion of COVID-19 infection by PCR in patients undergoing ASCT or CAR-T cell therapy.

**Final voting: agree 87.88%, abstain 12.12%, disagree 0% (0/33).**

**WP5: HM management in the COVID-19 pandemic: AML/MDS/acute lymphoblastic leukemia**

**Should any modification to standard of care treatment of MDS during the COVID-19 pandemic be implemented?**

**STATEMENT 23: A risk-adapted treatment strategy based on patient's condition, therapeutic goals, and individual risk by revised International Prognostic Scoring System (IPSS-R) should be adopted also in the pandemic.**

Patients with lower-risk MDS (IPSS-R score <3.5) are usually red blood cell transfusion-dependent and the primary aim should be to minimize transfusions, decrease hospital visits, and avoid potential shortage of blood products. The transfusion threshold should be based on the patient's clinical condition and reduced to a hemoglobin <7 g/dl whenever possible. Therapies driven to improve anemia (erythropoietic-stimulating agents, lenalidomide, and luspatercept) or thrombocytopenia (thrombopoietin agonists) should be started or continued as planned. Transfusions and those therapies should be ideally delivered and given at home, whenever possible. The start of immunosuppressive therapies should be delayed but continued in those already responding to treatment. For higher-risk MDS (IPSS-R score  $\geq 3.5$ ), doctors should distinguish three different situations: (i) high priority (patients whose condition is life-threatening or clinically unstable and/or a planned treatment resulting in a significant clinical benefit): treatment with hypomethylating agents (HMAs) should be started without delay. In those responding, HMAs should be continued as planned, but a short delay between cycles could be considered after at least six cycles of treatment. Targeted therapies and clinical trials should be taken into account; (ii) intermediate priority (patients whose condition is not

life-threatening, with moderate cytopenias, and fit): a short delay starting treatment could be considered depending on the local hospital and intensive care unit (ICU) availability; and (iii) low priority (patients with stable clinical conditions, for whom treatment is unlikely to provide a significant benefit, relapsed/refractory without eligibility for salvage therapies, and/or with multiple comorbidities): best supportive care is indicated.

**Final voting: agree 84.85%, abstain 12.12%, disagree 3.03% (1/33).**

**Should any modification to standard of care treatment of acute myeloid leukemia be implemented during the COVID-19 pandemic?**

**STATEMENT 24: Intensive chemotherapy should be offered without delay for eligible patients both at diagnosis and relapse. Low-intensity therapies (i.e. HMA +/- venetoclax) might be preferable for older (>65 years of age) and/or unfit patients. For consolidation, the use of intermediate-dose cytarabine and/or reducing the number of cycles could be considered. Treatment of acute promyelocytic leukemia (APL) should not be modified.**

Acute myeloid leukemia (AML) is an emergency medical condition in most cases and treatment cannot be postponed. Intensive chemotherapy is and should be the standard of care for fit patients with AML, even during the COVID-19 pandemic. Decreasing the number of cycles during post-remission therapy (intermediate dose cytarabine, 1.0-1.5 g/m<sup>2</sup>), especially in some prognostically favorable instances (i.e. *CBF* AML or *NPM1<sup>mut</sup>/FLT3 ITD<sup>neg</sup>* AML), can be considered to reduce the duration of neutropenia and hospitalization without affecting efficacy in selected cases. Potentially curable refractory/relapsed patients in whom intensive chemotherapy could serve as a bridge to HSCT should also be treated without delay. Only in SARS-CoV-2-infected patients without proliferative disease or low transfusion requirements may treatment be postponed until the infection is resolved. Treatment of older or unfit patients, e.g. with HMAs or low-dose cytarabine coupled with venetoclax, should be started in most instances as it has been shown to induce high remission rates, can minimize transfusion requirements, and reduce hospital stay. Low-risk APL should be treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), whereas in high-risk patients idarubicin should be added to ATRA +/- ATO.

**Final voting: agree 84.85%, abstain 15.15%, disagree 0% (0/33).**

**Should any modification to standard of care treatment of acute lymphoblastic leukemia during the COVID-19 pandemic be implemented?**

**STATEMENT 25: During the COVID-19 pandemic initial induction, intensive post-remission therapy, and maintenance therapy of acute lymphoblastic leukemia (ALL) should be given with as few modifications as possible in**

**children, adolescents and young adults (AYA), as well as in adult patients. All phases of therapy and second-line treatments for refractory/relapsed patients should be started without delay. For Philadelphia chromosome (Ph)-positive ALL a chemotherapy-free approach should be considered.**

In ALL, modifications of the treatment plan are likely to be associated with poorer outcomes. Adults with additional risk factors for fatal COVID-19 (i.e. diabetes, asthma or chronic obstructive pulmonary disorders, and obesity) should be closely followed. Steroids are considered safe for COVID-19 management and crucial for ALL, hence, they should be used without dose modification in all instances. In Ph-negative ALL, the general recommendation is to deliver ALL therapy without modifications. For adult patients with Ph-positive ALL, especially if a high COVID-19 incidence and hospital occupancy are present, a tyrosine-kinase inhibitor (TKI) with steroids is favored over intensive multidrug induction chemotherapy for initial treatment. In sharp contrast, intensive multidrug induction chemotherapy is recommended for children and AYA ALL patients. Aggressive post-remission therapy should be administered as scheduled, but the use of rituximab for consolidation is controversial due to the frequent need of hospital visits that could put patients at risk. Patients with relapsed or resistant ALL should be treated on a case-by-case basis and considering the availability of clinical trials.

**Final voting: agree 93.94%, abstain 6.06%, disagree 0% (0/33).**

**Should standard of care treatment be modified or stopped in an SARS-CoV-2-positive MDS, AML, blast phase of MPN/CML, ALL patient with asymptomatic or mild COVID-19 disease?**

**STATEMENT 26: Decisions about administering AML-, ALL-, and MDS-directed therapy in patients with asymptomatic or mild COVID-19 should consider the indication for treatment, goals of care, treatment intensity, and patient's history of tolerance to treatment. Delaying treatment until at least 2 weeks after resolution of symptoms and SARS-CoV-2 PCR negativity is recommended whenever possible.**

Delaying treatment until COVID-19 symptoms have resolved is recommended whenever possible and should be made on a case-by-case basis, also considering treatment intensity. Lower-risk MDS patients responding to erythropoiesis-stimulating agents, luspatercept or lenalidomide, as well as higher-risk MDS patients responding to HMAs beyond the third cycle without hematological toxicity should continue their therapy as planned, especially if treatment can be delivered at home. Treatment of the remaining MDS patients should be postponed. Intensive chemotherapy in AML or ALL should be delayed. In newly diagnosed patients with AML or ALL, low-intensity therapies to avoid progression could be used (i.e. prednisone plus central nervous system prophylaxis in ALL and hydroxyurea and/or HMAs or

*FLT3* inhibitors in AML). AML, ALL, or APL consolidation and maintenance therapies could be delayed. Thrombosis prophylaxis is recommended if asparaginase is to be used and asparaginase should be omitted if thrombotic events are present. A low-intensity therapy as a bridge to HSCT in patients with a high risk of progression could be considered. Patients already under active treatment, especially if prolonged myelosuppression is expected (i.e. chemotherapy, conditioning regimen, first three HMA cycles), must be admitted to a COVID-19 unit and closely monitored. Restarting treatment should be based on resolution of COVID-19 disease, especially if COVID-19 IgG antibodies are present.

**Final voting: agree 87.88%, abstain 12.12%, disagree 0% (0/33).**

**Should the standard of care treatment be modified or stopped in a SARS-CoV-2-positive patient with AML, blast phase of MPN/CML, ALL, or MDS and severe COVID-19 disease?**

**STATEMENT 27: All AML, ALL, and MDS patients should interrupt any active treatment of his/her HM and receive the best available therapy for COVID-19 along with the best supportive care for HM.**

The risk of death due to COVID-19 in these patients is very high. Any treatment driven to cure/avoid progression of their HM could substantially increase this risk and should be avoided until resolution of COVID-19. Patients must be treated in a COVID-19 unit according to institutional policy. As with other patients with severe COVID-19 disease, admission to ICU should be favored and based on their individual prognosis and expectancy of life.

**Final voting: agree 87.88%, abstain 12.12%, disagree 0% (0/33).**

**Should allogeneic hematopoietic cell transplantation for patients with AML, blast phase of MPN/CML, ALL, or MDS be postponed, or conditioning regimen modified during the pandemic?**

**STATEMENT 28: Allogeneic HSCT is a curative treatment approach for patients with MDS, AML, and ALL. If indicated, a deferral of the HSCT or modification of the planned conditioning regimen is not justified but can be considered on a case-by-case basis. In case of COVID-19 hot spot regions and/or lack of ICU beds, transferring the patient to other centers should be considered.**

Patients with COVID-19 after HSCT have a severe course and a higher risk of mortality. In contrast, any delay in postponing HSCT exposes patients to a high probability of relapse. A perceived higher risk due to the COVID-19 pandemic does not justify a reduction of the conditioning intensity.

**Final voting: agree 90.91%, abstain 9.09%, disagree 0% (0/33).**

**WP6: HM management in the COVID-19 pandemic: MPN/CML**

**How to treat MPN or CML in case of asymptomatic or mild/moderate symptomatic COVID-19?**

**STATEMENT 29:** In case of asymptomatic or mild/moderate COVID-19, newly diagnosed CML patients should initiate CML treatment without modifications; moreover there is no indication to interrupt or modify TKI therapy in previously diagnosed CML patients on continuous drug treatment. Likewise, therapy for MPN should not be adjusted in this situation.

Therapies used to treat MPN/CML are not expected to increase the risk of evolution to severe/very severe COVID-19 and treatment interruption may expose patients to loss of response, or in the case of ruxolitinib, worsening of inflammatory symptoms.<sup>111</sup>

**Final voting:** agree 93.94%, abstain 6.06%, disagree 0% (0/33).

**How to treat MPN or CML in the case of COVID-19 requiring hospitalization (severe or very severe)?**

**STATEMENT 30:** Treatment initiation in newly diagnosed CML with severe/critical COVID-19 disease should be evaluated on a case-by-case basis, considering the urgency of remission induction. In case of previously diagnosed CML patients, there is no indication to systematically interrupt or modify TKI therapy. Attention should be paid to the impact of potential TKI/anti-COVID-19 drug-drug interactions. In MPNs, particular attention should be paid to patients receiving ruxolitinib. Otherwise, therapies such as anticoagulants or cytoreductive therapy may need to be adjusted depending upon the patient's individual clinical scenario.

In CML, the decision to interrupt TKI treatment in case of admission due to COVID-19 needs to be made on a case-to-case basis considering time on TKI, response to TKI, type of TKI, and risk of CML relapse. To note, TKIs are not considered immunosuppressive, and it is expected that almost all patients still respond after a TKI discontinuation. In patients with concomitant TKI-related organ damage such as cardiovascular or pulmonary toxicity, the TKI should be stopped until both COVID-19 and adverse events are resolved. For MPN patients with COVID-19, ruxolitinib discontinuation could be harmful.<sup>111</sup>

**Final voting:** agree 90.91%, abstain 9.09%, disagree 0% (0/33).

**Is there any indication to change the current approach to SARS-CoV-2 negative CML patients during the COVID-19 pandemic?**

**STATEMENT 31:** The general approach to CML patients does not require major modifications in the pandemic, whereas monitoring and supportive care need careful

**planning to guarantee safe outpatient treatment of CML patients. Home delivery and telemedicine should be encouraged.**

Treatment in newly diagnosed CML should not be postponed as remission induction is considered beneficial, even in the pandemic. Caution is advised during the first 3 months of TKI treatment, however, as severe cytopenia may occur, thus possibly increasing the severity of COVID-19. The pandemic should not affect the choice of TKI. A recent study found an increased mortality risk in CML patients with COVID-19 when treated with imatinib, but this may be confounded by older age, and access to and quality of health services.<sup>112</sup> Patients already on treatment with TKIs should continue their treatment. In case of pulmonary side-effects of TKIs, SARS-CoV-2 infection should be ruled out, and side-effects aggressively managed. A switch to another TKI may be considered. In patients with long-lasting molecular remission (MR) 4 or better, TKI may be stopped according to current guidelines and patients may be molecularly monitored monthly for the first 6 months. During the pandemic, monitoring frequency and in-person visits should not be modified. In patients progressing to blast crisis, the indication for treatment should not be modified or postponed. Finally, in women with CML who plan to become pregnant and in pregnant women with CML, interferon treatment does not require adaptation due to the COVID-19 pandemic.

**Final voting:** agree 96.97%, abstain 3.03%, disagree 0% (0/33).

**Is there any indication to change the current approach to MPN patients during the COVID-19 pandemic?**

**STATEMENT 32:** The general approach to MPN patients does not require modifications due to the COVID-19 pandemic, whereas monitoring and supportive care need careful planning to guarantee safe treatment of MPN patients outside the hospital setting. Home delivery and telemedicine should be encouraged.

Many patients with MPNs under ongoing treatment have stable disease and can be supported with remote monitoring; in some countries this care is already provided under guidelines by specialist nurses, pharmacists, or family doctors. Some patients, e.g. those with advanced phase or aggressive myelofibrosis and transfusion dependence, require closer monitoring mostly in a hospital setting. For selected MPN patients with stable disease, intensity of monitoring could likely be reduced for a limited time provided the patient has good links to their routine team. For patients initiating or changing therapy, the individual decision should be based on the advantage of initiating an effective treatment, the frequency of monitoring during the first months of therapy, and the risk of COVID-19. In polycythemia vera (PV) and essential thrombocythemia (ET), delaying treatment initiation can increase the risk of thrombosis. In myelofibrosis, initiation of ruxolitinib requires specific considerations. For those patients



already taking ruxolitinib, stopping the drug whilst having COVID-19 seems to be harmful. Overall, there is no indication to modify current MPN guidelines even in the pandemic.

**Final voting: agree 96.97%, abstain 3.03%, disagree 0% (0/33).**

**Is SCT to be postponed for MPN/CML patients during the pandemic?**

**STATEMENT 33: HSCT should not be postponed for MPN/CML patients with strong indication for HSCT, while measures should be taken to guarantee post-HSCT treatment, monitoring, and care for patients who acquire SARS-CoV-2 after HSCT.**

SARS-CoV-2-negative patients with MPN/CML can receive HSCT as indicated. In the case of SARS-CoV-2-positive patients with high-risk MPN/CML, HSCT should be deferred until the patient is asymptomatic and has two negative PCR swabs taken at least 24 h apart. In patients with low-risk disease, who were asymptomatic or only mildly symptomatic with upper respiratory tract symptoms, a deferral of at least 14 days after the first negative PCR test is indicated, with a new PCR test recommended before conditioning; for those with moderate to severe COVID-19, it is recommended to defer HSCT for at least 3 months.

**Final voting: agree 96.97%, abstain 3.03%, disagree 0% (0/33).**

### Conclusions

Using a structured method and relying on a panel of experts, we have developed a detailed set of clinical statements to guide health care professionals and assist them in overcoming many of the clinical issues in HM management during the COVID-19 pandemic. The % rate of 'abstain' seen in some statements is due to the fact that several sub-specialized working groups produced statements that were subsequently voted upon in a plenary session by all co-authors, among whom some felt were outside their 'core expertise area'.

This set of recommendations reflects the knowledge at the time point of writing. This implies that based on the high dynamics of the COVID-19 pandemic, the rapid increase in our understanding of COVID-19 biology, and the fast changes in the vaccination status of the general population, this expert consensus should be considered as a dynamic repository of clinical recommendations.

### ACKNOWLEDGEMENTS

The panel would like to acknowledge the work of Klizia Marinoni and Delanie Young, from the Scientific and Medical Division at ESMO, for the project coordination and editorial assistance.

### FUNDING

None declared.

### DISCLOSURE

CB reports honoraria from Roche/Genentech, Janssen, BeiGene, Novartis, Pfizer, Incyte, AbbVie, Gilead Sciences, Celltrion, MorphoSys, Regeneron; he reports consulting or advisory role: Gilead Sciences, Janssen, Roche, Pfizer, BeiGene, Celltrion, AbbVie, Incyte, Regeneron, MorphoSys, Novartis; he reports speaker's engagement: Roche, Janssen, BeiGene, Celltrion, AbbVie, Pfizer, Gilead Sciences; he reports research funding: Roche/Genentech, Janssen, Celltrion, Merck Sharp & Dohme (MSD), Pfizer, Amgen.

MD reports honoraria as Advisory Board Member of AstraZeneca, Bayer, BeiGene, Celgene, Genmab, Gilead, Incyte, Janssen, Lilly, MorphoSys, Novartis, Roche; he reports honoraria for speaker's engagement from Amgen, AstraZeneca, Bayer, Celgene, Gilead, Janssen, Novartis, Roche; he reports institutional research grants from AbbVie, Bayer, Gilead, Celgene, Janssen, Roche.

AA-L has declared no conflicts of interest.

JA reports personal financial interests as advisory board and invited speaker from Incyte, advisory board from Malinckrodt, advisory board and invited speaker from Novartis, advisory board and invited speaker from Pfizer; she reports non-financial interests as principal investigator from Incyte, principal investigator from Novartis.

LA received advisory honoraria from Roche, Celgene, Janssen-Cilag, Verastem, Eusa Pharma, Incyte, ADC Therapeutics and Gilead; research support from Gilead, and travel expenses from Roche, Celgene, Janssen-Cilag, and Eusa Pharma; speakers bureau from Novartis.

CB has declared no conflicts of interest.

LB reports Advisory Committee activities for AbbVie, Amgen, Astellas, Bristol Myers Squibb (BMS), Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer, Sanofi, Seattle Genetics and has research support from Bayer and Jazz Pharmaceuticals.

PC has declared no conflicts of interest.

M GDP has declared no conflicts of interest.

MD reports personal fees from Amgen, personal fees from Takeda, personal fees from Janssen, personal fees from BeiGene, personal fees from BMS, outside the submitted work.

SD reports personal financial interests as advisory board, invited speaker, fellow funding, and coordinating PI from BeiGene, writing engagement from Karger, advisory board and coordinating PI from Sanofi, funding, and other from Janssen; she reports non-financial interests as advisory role at British Society for Haematology Lymphoma Special Interest Group, advisory role at Lymphoma Action, member of board of directors at WMUK Charity.

HTE has declared no conflicts of interest.

RF reports honoraria for advisory boards and/or speaker bureau from Janssen, Gilead, AbbVie, Amgen, Novartis, Roche, Incyte, Pfizer, all outside the submitted work.

PG reports grants and personal fees from AbbVie, grants and personal fees from Acerta/AstraZeneca, personal fees from BeiGene, personal fees from Celgene/Juno/BMS, grants and personal fees from Janssen, personal fees

from Lilly/Loxo, personal fees from MEI, personal fees from Roche, personal fees from Sanofi, personal fees from ArQule/MSD, outside the submitted work;

MGdS reports grants, personal fees, non-financial support and other from Gilead Sciences, grants from AstraZeneca, personal fees, non-financial support, and other from Janssen Cilag, personal fees and non-financial support from Roche, non-financial support from AbbVie, personal fees and non-financial support from BMS, personal fees and non-financial support from MSD, personal fees and non-financial support from Takeda, personal fees from Novartis, personal fees from ADC Therapeutics, outside the submitted work.

JG reports personal fees from AbbVie, grants and personal fees from AstraZeneca, grants and personal fees from BMS/Celgene, grants and personal fees from Janssen, personal fees from Kite/Gilead, personal fees from MorphoSys, personal fees from Novartis, personal fees from TG Therapeutics, outside the submitted work.

RH has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda.

CH reports grants and personal fees from Novartis, grants and personal fees from BMS, personal fees from Sierra Oncology, personal fees from CTI pharmaceuticals, personal fees from Janssen, personal fees from Geron, grants and personal fees from AOP Orphan Pharma, personal fees from Galecto, grants, personal fees and other from Constellation, outside the submitted work.

MH reports personal fees from Novartis, personal fees from Pfizer, personal fees from Roche, personal fees from AbbVie, personal fees from Daiichi Sankyo, personal fees from Bayer Pharma AG, personal fees from Jazz Pharmaceuticals, personal fees from BMS, personal fees from Tolremo, outside the submitted work.

BK has received honoraria for lectures from Ipsen, Novartis and MSD (all outside of the submitted work).

J-JK reports consulting fees and honoraria from Novartis, consulting fees from AbbVie, honoraria from AOP Orphan Pharma, participation on a monitoring board or advisory board from BMS/Celgene, participation on a monitoring board or advisory board from Incyte.

NK reports grants and honoraria from Neovii, honoraria from Sanofi, grants and honoraria from Jazz, grants and honoraria from Celgene, grants and honoraria from Riemser, honoraria from Gilead/Kite, honorarium from AOP Orphan Pharma, grants and honorarium from Novartis, honorarium from Amgen.

PM reports personal fees from Celgene, Amgen, Janssen, AbbVie, Sanofi, outside the submitted work.

JP has declared no conflicts of interest.

FP has declared no conflicts of interest.

DR received honoraria from Incyte, Novartis Pharma, Pfizer; clinical trial steering committee membership:

Novartis; membership on advisory boards: Incyte, Novartis Pharma, Pfizer.

J-MR reports grants and honoraria from Novartis, Amgen, Pfizer, Takeda, Incyte, and Servier.

TR has declared no conflicts of interest.

JF-M reports consulting and advisory boards honoraria (received by CUN ) from AbbVie, Amgen, BMS, Celgene, Janssen, GlaxoSmithKline, Karyopharm, MSD, Novartis, Takeda, Sanofi, SecuraBio, Regeneron, Roche, outside the submitted work.

VS has declared no conflicts of interest.

GFS reports personal fees and other from AbbVie, other from Amgen, other from Astellas, other from Boehringer-Ingelheim, grants, personal fees and other from Celgene, other from Helsinn Healthcare, grants, personal fees, and other from Janssen-Cilag, grants and other from Novartis, other from Onconova, grants, personal fees and other from Roche, and other from Takeda, outside the submitted work.

PS reports honoraria from Amgen, Celgene, Janssen, Karyopharm, SkylineDx, Takeda, and research support from Celgene, Janssen, Amgen, Takeda, BMS, SkylineDx, Karyopharm, all outside the submitted work.

MvL-T has received travel grants and honoraria from Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merck, CDDF, Pfizer, Medac, Thermo Fisher, AstraZeneca; is a consultant for Celgene, Gilead, Oncopeptides, MSD, 4D Pharma, Janssen, Shionogi and received research funding from BMBF, Deutsche Jose Carreras Leukämie-Stiftung, IZKF Jena, Novartis, Gilead, Deutsche Krebshilfe, Celgene, Oncopeptides, Deutsche Forschungsgemeinschaft (DFG).

CW has declared no conflicts of interest.

GP reports grants from Amgen, grants, personal fees and non-financial support from Merck, grants and non-financial support from AstraZeneca, grants and personal fees from Roche, grants and personal fees from BMS, grants from Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, outside the submitted work.

FP reports grants from Novartis, Celgene, BMS, Abbvie, Karyopharma, Janssen.

## REFERENCES

- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.
- Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397:220-232.
- Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. *Lancet*. 2020;395:1919-1926.
- Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with hematological malignancies in Italy: a retrospective, multicentre, cohort study. *Lancet Haematol*. 2020;7:e737-e745.
- Garcia-Suarez J, de la Cruz J, Cedillo A, et al. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. *J Hematol Oncol*. 2020;13:133.

6. Wood WA, Neuberg DS, Thompson JC, et al. Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. *Blood Adv.* 2020;4:5966-5975.
7. Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. *Blood.* 2020;136:2881-2892.
8. Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. *Blood.* 2020;136:3033-3040.
9. Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. *Blood.* 2020;136:1134-1143.
10. Regalado-Artamendi I, Jimenez-Ubieto A, Hernandez-Rivas JA, et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. *Hemasphere.* 2021;5:e538.
11. Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. *Lancet Haematol.* 2021;8:e185-e193.
12. Passamonti F, Romano A, Salvini M, et al. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. *Br J Haematol.* 2021;195:371-377.
13. Toyoshima Y, Nemoto K, Matsumoto S, et al. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. *J Hum Genet.* 2020;65:1075-1082.
14. Herzog Tzarfati K, Gutwein O, Apel A, et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. *Am J Hematol.* 2021;96:1195-1203.
15. Maneikis K, Sablauskas K, Ringeleviciute U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. *Lancet Haematol.* 2021;8:e583-e592.
16. Benda M, Mutschlechner B, Ulmer H, et al. Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients. *Br J Haematol.* 2021;195:523-531.
17. Greenberger LM, Saltzman LA, Seneff JW, et al. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. *Cancer Cell.* 2021;39:1031-1033.
18. Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. *Blood.* 2021;137:3165-3173.
19. Roeker LE, Knorr DA, Thompson MC, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. *Leukemia.* 2021;35:2703-2705.
20. Perry C, Luttwak E, Balaban R, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. *Blood Adv.* 2021;5:3053-3061.
21. Ghione P, Gu JJ, Attwood K, et al. Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell directed therapies. *Blood.* 2021;138:811-814.
22. Lim SH, Campbell N, Johnson M, et al. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. *Lancet Haematol.* 2021;8:e542-e544.
23. Gurion R, Rozovski U, Itchaki G, et al. Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD20 antibodies. *Haematologica.* 2022;107(3):715-720.
24. Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. *Blood Cancer J.* 2021;11:138.
25. Van Oekelen O, Gleason CR, Agte S, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. *Cancer Cell.* 2021;39:1028-1030.
26. Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. *J Hematol Oncol.* 2021;14:81.
27. Bird S, Panopoulou A, Shea RL, et al. Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. *Lancet Haematol.* 2021;8:e389-e392.
28. Terpos E, Trougakos IP, Gavriatopoulou M, et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. *Blood.* 2021;137:3674-3676.
29. Pimpinelli F, Marchesi F, Piaggio G, et al. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. *J Hematol Oncol.* 2021;14:119.
30. Harrington P, de Lavallade H, Doores KJ, et al. Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. *Leukemia.* 2021;35:3573-3577.
31. Harrington P, Doores KJ, Radia D, et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. *Br J Haematol.* 2021;194:999-1006.
32. Harrington P, Harrison CN, Dillon R, et al. Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). *Br J Haematol.* 2021;193:692-696.
33. Cowling BJ, Ali ST, Ng TWY, et al. Impact assessment of non-pharmaceutical interventions against coronavirus disease 2019 and influenza in Hong Kong: an observational study. *Lancet Public Health.* 2020;5:e279-e288.
34. Bartoszko JJ, Farooqi MAM, Alhazzani W, Loeb M. Medical masks vs N95 respirators for preventing COVID-19 in healthcare workers: a systematic review and meta-analysis of randomized trials. *Influenza Other Respir Viruses.* 2020;14:365-373.
35. Cheng VC, Wong SC, Chuang VW, et al. The role of community-wide wearing of face mask for control of coronavirus disease 2019 (COVID-19) epidemic due to SARS-CoV-2. *J Infect.* 2020;81:107-114.
36. Lewnard JA, Liu VX, Jackson ML, et al. Incidence, clinical outcomes, and transmission dynamics of severe coronavirus disease 2019 in California and Washington: prospective cohort study. *BMJ.* 2020;369:m1923.
37. Matrajt L, Leung T. Evaluating the effectiveness of social distancing interventions to delay or flatten the epidemic curve of coronavirus disease. *Emerg Infect Dis.* 2020;26:1740-1748.
38. Cowling BJ, Zhou Y, Ip DK, et al. Face masks to prevent transmission of influenza virus: a systematic review. *Epidemiol Infect.* 2010;138:449-456.
39. Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nat Med.* 2020;26:676-680.
40. Cho SY, Park SS, Lee JY, et al. Successful prevention and screening strategies for COVID-19: focus on patients with haematologic diseases. *Br J Haematol.* 2020;190:e33-e37.
41. van de Haar J, Hoes LR, Coles CE, et al. Caring for patients with cancer in the COVID-19 era. *Nat Med.* 2020;26:665-671.
42. Weisel KC, Morgner-Miehlke A, Petersen C, et al. Implications of SARS-CoV-2 infection and COVID-19 crisis on clinical cancer care: report of the University Cancer Center Hamburg. *Oncol Res Treat.* 2020;43:307-313.
43. Lemaitre M, Meret T, Rothan-Tondeur M, et al. Effect of influenza vaccination of nursing home staff on mortality of residents: a cluster-randomized trial. *J Am Geriatr Soc.* 2009;57:1580-1586.
44. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med.* 2021;384:403-416.
45. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med.* 2020;383:2603-2615.
46. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet.* 2021;397:99-111.

47. Meisel R, Kuypers L, Dirksen U, et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. *Blood*. 2007;109:2322-2326.
48. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. *Influenza. Other Respir Viruses*. 2013;7(suppl 2):72-75.
49. Bitterman R, Eliakim-Raz N, Vinograd I, et al. Influenza vaccines in immunosuppressed adults with cancer. *Cochrane Database Syst Rev*. 2018;2:CD008983.
50. Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. *Lancet*. 2018;391:2116-2127.
51. Rieger CT, Liss B, Mellingshoff S, et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). *Ann Oncol*. 2018;29:1354-1365.
52. Mikulska M, Cesaro S, de Lavallade H, et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). *Lancet Infect Dis*. 2019;19:e188-e199.
53. Cordonnier C, Einarsdottir S, Cesaro S, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). *Lancet Infect Dis*. 2019;19:e200-e212.
54. Giesen N, Sprute R, Rüttrich M, et al. 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy. *Eur J Cancer*. 2021;147:154-160.
55. Wijn DH, Groeneveld GH, Vollaard AM, et al. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. *Eur J Cancer*. 2018;104:182-187.
56. Bayle A, Khettab M, Lucibello F, et al. Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1. *Ann Oncol*. 2020;31:959-961.
57. Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. *N Engl J Med*. 2021;384:1964-1965.
58. Sadoff J, Davis K, Douguilh M. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination - response from the manufacturer. *N Engl J Med*. 2021;384:1965-1966.
59. Bourguignon A, Arnold DM, Warkentin TE, et al. Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia. *N Engl J Med*. 2021;385:720-728.
60. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. *N Engl J Med*. 2021;384:2092-2101.
61. Larson KF, Ammirati E, Adler ED, et al. Myocarditis after BNT162b2 and mRNA-1273 vaccination. *Circulation*. 2021;144:506-508.
62. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. *N Engl J Med*. 2020;382:2081-2090.
63. Mondì A, Lorenzini P, Castilletti C, et al. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted in an Italian Reference Hospital. *Int J Infect Dis*. 2021;105:532-539.
64. Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. *Cell*. 2020;183:1901-1912.e9.
65. Hao S, Lian J, Lu Y, et al. Decreased B cells on admission associated with prolonged viral RNA shedding from the respiratory tract in coronavirus disease 2019: a case-control study. *J Infect Dis*. 2020;222:367-371.
66. van Kampen JJA, van de Vijver D, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun*. 2021;12:267.
67. Courtellement L, Guinard J, Guillaume C, et al. High performance of a novel antigen detection test on nasopharyngeal specimens for diagnosing SARS-CoV-2 infection. *J Med Virol*. 2021;93:3152-3157.
68. Peña-Rodríguez M, Viera-Segura O, García-Chagollán M, et al. Performance evaluation of a lateral flow assays for nasopharyngeal antigen detection for SARS-CoV-2 diagnosis. *J Clin Lab Anal*. 2021;35:e23745.
69. Pérez-García F, Romanyk J, Gómez-Herruz P, et al. Diagnostic performance of CerTest and Panbio antigen rapid diagnostic tests to diagnose SARS-CoV-2 infection. *J Clin Virol*. 2021;137:104781.
70. Pollock NR, Jacobs JR, Tran K, et al. Performance and implementation evaluation of the Abbott BinaxNOW rapid antigen test in a high-throughput drive-through community testing site in Massachusetts. *J Clin Microbiol*. 2021;59:e00083-21.
71. Thommes L, Burkert FR, Öttl KW, et al. Comparative evaluation of four SARS-CoV-2 antigen tests in hospitalized patients. *Int J Infect Dis*. 2021;105:144-146.
72. Merino P, Guinea J, Muñoz-Gallego I, et al. Multicenter evaluation of the Panbio™ COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection. *Clin Microbiol Infect*. 2021;27:758-761.
73. Silva J, Lucas C, Sundaram M, et al. Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. *medRxiv*. 2021.
74. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. *N Engl J Med*. 2020;383:1283-1286.
75. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA*. 2020;323:1843-1844.
76. Moreira VM, Mascarenhas P, Machado V, et al. Diagnosis of SARS-CoV-2 infection by RT-PCR using specimens other than naso- and oropharyngeal swabs: a systematic review and meta-analysis. *Diagnosics (Basel)*. 2021;11:363.
77. Stanoeva KR, van der Eijk AA, Meijer A, et al. Towards a sensitive and accurate interpretation of molecular testing for SARS-CoV-2: a rapid review of 264 studies. *Euro Surveill*. 2021;26:2001134.
78. Nawar T, Morjaria S, Kaltsas A, et al. Granulocyte-colony stimulating factor in COVID-19: is it stimulating more than just the bone marrow? *Am J Hematol*. 2020;95:E210-E213.
79. Zhang AW, Morjaria S, Kaltsas A, et al. The effect of neutropenia and filgrastim (G-CSF) in cancer patients with COVID-19 infection. *Clin Infect Dis*. 2022;74(4):567-574.
80. Fajgenbaum DC, June CH. Cytokine storm. *N Engl J Med*. 2020;383:2255-2273.
81. Peyvandi F, Artoni A, Novembrino C, et al. Hemostatic alterations in COVID-19. *Haematologica*. 2021;106:1472-1475.
82. Rhee C, Kanjilal S, Baker M, Klompas M. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue isolation? *Clin Infect Dis*. 2021;72:1467-1474.
83. Rao SN, Manissero D, Steele VR, Pareja J. A systematic review of the clinical utility of cycle threshold values in the context of COVID-19. *Infect Dis Ther*. 2020;9:573-586.
84. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. *N Engl J Med*. 2020;383:2586-2588.
85. Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. *N Engl J Med*. 2020;383:2291-2293.
86. Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. *Blood*. 2020;135:1912-1915.
87. Dreyling M, Aurer I, Federico M, et al. EHA/ESMO clinical practice guidelines for the management of malignant lymphoma: recommendations for the second phase of the COVID-19 pandemic. *Hemasphere*. 2021;5:e529.
88. Rossi D, Shadman M, Condoluci A, et al. How we manage patients with chronic lymphocytic leukemia during the SARS-CoV-2 Pandemic. *Hemasphere*. 2020;4:e432.
89. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol*. 2014;15:e538-e548.

90. Terpos E, Engelhardt M, Cook G, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). *Leukemia*. 2020;34:2000-2011.
91. Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network guidelines for the management of multiple myeloma-related complications. *Haematologica*. 2015;100:1254-1266.
92. Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. *J Clin Oncol*. 2013;31:2347-2357.
93. Kyriakou C, Molloy S, Vrionis F, et al. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). *Blood Cancer J*. 2019;9:27.
94. Terpos E, Zamagni E, Lentzsch S, et al. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. *Lancet Oncol*. 2021;22:e119-e130.
95. Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. *Blood Cancer J*. 2018;8:59.
96. Rogado J, Gullon P, Obispo B, et al. Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors. *Eur J Cancer*. 2021;148:58-60.
97. Martinez-Lopez J, Mateos MV, Encinas C, et al. Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. *Blood Cancer J*. 2020;10:103.
98. Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med*. 2021;384:693-704.
99. Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. *Am J Hematol*. 2020;95:548-567.
100. Rosinol L, Oriol A, Rios R, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. *Blood*. 2019;134:1337-1345.
101. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. *N Engl J Med*. 2017;376:1311-1320.
102. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2021;32:309-322.
103. Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, et al. Multiple myeloma: role of autologous transplantation. *Cancer Treat Rev*. 2020;82:101929.
104. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. *Lancet*. 2019;394:29-38.
105. Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. *Br J Haematol*. 2019;185:492-502.
106. Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. *Leukemia*. 2014;28:1573-1585.
107. Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. *Lancet*. 2019;394:2096-2107.
108. Dimopoulos MA, Dytfield D, Grosicki S, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. *N Engl J Med*. 2018;379:1811-1822.
109. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. *N Engl J Med*. 2019;381:727-738.
110. Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncol*. 2020;21:207-221.
111. Barbui T, Vannucchi AM, Alvarez-Larran A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. *Leukemia*. 2021;35:485-493.
112. Breccia M, Abruzzese E, Accurso V, et al. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. *Br J Haematol*. 2022;196:559-565.